Clinical Trials Logo

HER2-Positive Solid Tumors clinical trials

View clinical trials related to HER2-Positive Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT06328738 Recruiting - Colorectal Cancer Clinical Trials

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.

NCT ID: NCT04660929 Active, not recruiting - Breast Cancer Clinical Trials

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

NCT ID: NCT04521179 Completed - Clinical trials for HER2-positive Solid Tumors

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

Start date: December 7, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, phase II,multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.

NCT ID: NCT04501770 Not yet recruiting - Clinical trials for HER2-Positive Solid Tumors

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

Start date: August 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the recommended phase 2 dose (RP2D).

NCT ID: NCT04460456 Active, not recruiting - Clinical trials for HER2 Positive Solid Tumors

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Start date: July 27, 2020
Phase: Phase 1
Study type: Interventional

A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

NCT ID: NCT04280341 Recruiting - Clinical trials for HER2-Positive Solid Tumors

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

Start date: June 3, 2020
Phase: Phase 1
Study type: Interventional

This is a non-randomized, open-label, single-arm, multicenter Phase I clinical trial which will evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody in Treatment of HER2-Positive Advanced Malignant Solid Tumors.

NCT ID: NCT04278144 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Start date: February 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

NCT ID: NCT04189211 Active, not recruiting - Clinical trials for HER2-Positive Solid Tumors

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients with HER2-Positive Solid Tumors (breast cancer or gastric cancer)。